Impact of Chemotherapy Dose Intensity on Breast Cancer Outcomes
Author Information
Author(s): Loibl Sibylle, Skacel Tomas, Nekljudova Valentina, Lück Hans Joachim, Schwenkglenks Matthias, Brodowicz Thomas, Zielinski Christoph, von Minckwitz Gunter
Primary Institution: German Breast Group
Hypothesis
Does the Relative Total Dose Intensity (RTDI) affect the short and long-term outcomes in metastatic breast cancer patients receiving chemotherapy?
Conclusion
Optimizing RTDI above 85% appears to improve long-term outcomes for metastatic breast cancer patients receiving first-line chemotherapy.
Supporting Evidence
- Higher RTDI was correlated with shorter time to disease progression.
- Patients with RTDI below 85% had shorter overall survival compared to those with higher RTDI.
- The study included data from three randomized trials with a total of 934 patients.
Takeaway
Giving the right amount of chemotherapy helps breast cancer patients live longer. If they get less than 85% of the planned dose, it can be bad for their health.
Methodology
Pooled analysis of individual patient data from three randomized trials focusing on RTDI's impact on efficacy measures.
Potential Biases
Potential bias due to the retrospective analysis and missing data on further treatments.
Limitations
Retrospective nature, lack of quality of life data, and exclusion of one treatment arm due to inaccurate reporting.
Participant Demographics
Median age of participants was 56 years, with a mix of prior chemotherapy and hormonal receptor statuses.
Statistical Information
P-Value
0.0086
Confidence Interval
95% CI [83-119]
Statistical Significance
p = 0.0086
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website